News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–51
Matches
51
Sources here
9
Companies here
1
Search results Stored financial headlines

Active search

51 matching headlines

Ticker or company: PCRXMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

TradingKey Earnings Main company 🇺🇸 United States

Pacira Biosciences Inc (PCRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Pacira Biosciences Inc (PCRX), categorizing its revenue by business segments for the fiscal year 2025. It shows that EXPAREL contributes the largest proportion of revenue, followed by ZILRETTA, iovera, and Bupivacaine liposome injectable suspension. The report …

PCRX main company
Sharemaestro market context Trend signal active 52 weeks -11.0% PCRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Pacira Biosciences Inc (PCRX) Cash Flow

This article provides a detailed cash flow statement for Pacira Biosciences Inc (PCRX), covering quarterly and annual data for various cash flow components from operating, investing, and financing activities. It includes year-over-year percentage changes and absolute financial figures for numerous periods. The document also …

PCRX main company
Sharemaestro market context Trend signal active 52 weeks -11.0% PCRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Pacira Biosciences, Inc. Revenue Breakdown – FWB:82P

Pacira Biosciences, Inc. (FWB:82P) generated €618.48 million in revenue last year, primarily from its Non-opioid Pain Management and Regenerative Health Solutions segment. This revenue largely came from the United States, European Union, United Kingdom, and Canada, though it represents a decrease from the previous …

PCRX main company
Sharemaestro market context Trend signal active 52 weeks -11.0% PCRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Earnings Main company 🇺🇸 United States

Pacira BioSciences, Inc. (PCRX) stock price, news, quote and history

This article provides comprehensive financial information for Pacira BioSciences, Inc. (PCRX), including its current stock price, historical data, key financial metrics, and analyst ratings. It details the company's focus on non-opioid pain management solutions and regenerative health, outlining its flagship products like EXPAREL and …

PCRX main company
Sharemaestro market context Trend signal active 52 weeks -11.0% PCRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Pacira Biosciences Inc (PCRX) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Pacira Biosciences Inc (PCRX), highlighting its current valuation score of 8.28, which ranks 102 out of 155 in the Pharmaceuticals industry. The company's P/E ratio is 205.94, which is below its recent high and above its recent …

PCRX main company
Sharemaestro market context Trend signal active 52 weeks -11.0% PCRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Pacira Biosciences Inc (PCRX) Institutional Confidence

Pacira Biosciences Inc (PCRX) shows an institutional confidence score of 10.00, ranking first in the Pharmaceuticals industry. Institutional shareholding stands at 122.53%, indicating a 1.68% quarter-over-quarter increase. James Simons is the largest institutional shareholder, holding 4.64% of the shares outstanding.

PCRX main company
Sharemaestro market context Trend signal active 52 weeks -11.0% PCRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Ad-hoc-news.de Earnings Main company 🇺🇸 United States

Pacira stock trades steady as EXPAREL revenue supports margins

Pacira BioSciences (PCRX) stock is trading steadily due to strong EXPAREL revenue and resilient margins, balancing moderate growth with efficient operations. The company, focused on non-opioid pain management, reported $180 million in quarterly revenue and over $700 million annually in fiscal 2024, with EXPAREL …

PCRX main company
Sharemaestro market context Trend signal active 52 weeks -11.0% PCRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GlobeNewswire Earnings Main company 🇺🇸 United States

Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026

Pacira BioSciences announced it will release its second quarter 2026 financial results after market close on Tuesday, August 4, 2026. The company will host a live conference call and webcast at 4:30 p.m. ET to discuss the results, with pre-registration available for those wishing …

PCRX main company
Sharemaestro market context Trend signal active 52 weeks -11.0% PCRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Pacira will pair Aug. 4 results with a live investor Q&A

Pacira BioSciences (Nasdaq: PCRX) announced it will report its second quarter 2026 financial results after U.S. market close on Tuesday, August 4, 2026. A live conference call and webcast will follow at 4:30 p.m. ET, requiring pre-registration for telephone Q&A participation. A replay will …

PCRX main company
Sharemaestro market context Trend signal active 52 weeks -11.0% PCRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
DirectorsTalk Interviews Earnings Main company 🇺🇸 United States

Pacira BioSciences, Inc. (PCRX) Stock Analysis: Exploring A Potential 17% Upside

Pacira BioSciences, Inc. (NASDAQ: PCRX), a healthcare leader in non-opioid pain management, shows potential for a 17.03% upside according to market analysis. The company, with a market cap of $997.47 million, currently trades at $25.35 and exhibits a promising forward P/E ratio, strong free …

PCRX main company
Sharemaestro market context Trend signal active 52 weeks -11.0% PCRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Traders Daily Market update Main company 🇺🇸 United States

Understanding the Setup: (PCRX) and Scalable Risk

This article analyzes Pacira Biosciences Inc. (NASDAQ: PCRX) with a focus on its current market setup and risk scalability. The analysis indicates neutral near-term readings, but a mid-term strong sentiment may be pausing, presenting an exceptional 34.9:1 risk-reward short setup. Three AI-generated institutional trading …

PCRX main company
Sharemaestro market context Trend signal active 52 weeks -11.0% PCRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
ad-hoc-news.de Earnings Main company 🇺🇸 United States

Pacira stock trades steady as investors weigh Q1 2026 revenue and margin trends

Pacira BioSciences (PCRX) reported a mixed Q1 2026, with net product sales rising to $182.5 million, up 6.6% year-on-year, driven by its non-opioid pain-management products like EXPAREL. However, net income decreased to $9.8 million from $17.4 million in Q1 2025 due to higher operating …

PCRX main company
Sharemaestro market context Trend signal active 52 weeks -11.0% PCRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Ad Hoc News Earnings Main company 🇺🇸 United States

Pacira BioSciences stock trades steady as Exparel revenue supports valuation

Pacira BioSciences stock performance is closely linked to its flagship non-opioid pain management drug, Exparel, with investors focusing on revenue trends and cash generation. While Exparel's revenue growth has been steady, the company's profitability shows variability due to balancing growth investments with disciplined expense …

PCRX main company
Sharemaestro market context Trend signal active 52 weeks -11.0% PCRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Market update Main company 🇺🇸 United States

PCRX6079820 Bond Coupon Profile — Rate & Payments

This article provides a bond coupon profile for Pacira Biosciences, Inc.'s PCRX6079820 bond, detailing its 2.125% interest rate with a maturity date of May 15, 2029. It highlights the current coupon rate of 2.13% and indicates the next payment is scheduled for November 16, …

PCRX main company
Sharemaestro market context Trend signal active 52 weeks -11.0% PCRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Market update Main company 🇺🇸 United States

PCRX6079820 Bond Profile — Key Metrics

This article provides key metrics for the Pacira Biosciences, Inc. 2.125% 15-MAY-2029 corporate bond, identified as PCRX6079820. It details the bond's issue and maturity dates, outstanding amount, face value, and coupon rate. Additionally, it offers a brief company profile for Pacira Biosciences, Inc., highlighting …

PCRX main company
Sharemaestro market context Trend signal active 52 weeks -11.0% PCRX stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context